Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1 and TIGIT CD4 T Cells
Overview
Authors
Affiliations
Combination anti-retroviral drug therapy (ART) potently suppresses HIV-1 replication but does not result in virus eradication or a cure. A major contributing factor is the long-term persistence of a reservoir of latently infected cells. To study this reservoir, we established a humanized mouse model of HIV-1 infection and ART suppression based on an oral ART regimen. Similar to humans, HIV-1 levels in the blood of ART-treated animals were frequently suppressed below the limits of detection. However, the limited timeframe of the mouse model and the small volume of available samples makes it a challenging model with which to achieve full viral suppression and to investigate the latent reservoir. We therefore used an latency reactivation assay that allows a semiquantitative measure of the latent reservoir that establishes in individual animals, regardless of whether they are treated with ART. Using this assay, we found that latently infected human CD4 T cells can be readily detected in mouse lymphoid tissues and that latent HIV-1 was enriched in populations expressing markers of T cell exhaustion, PD-1 and TIGIT. In addition, we were able to use the latency reactivation assay to demonstrate that HIV-specific TALENs can reduce the fraction of reactivatable virus in the latently infected cell population that establishes , supporting the use of targeted nuclease-based approaches for an HIV-1 cure. HIV-1 can establish latent infections that are not cleared by current antiretroviral drugs or the body's immune responses and therefore represent a major barrier to curing HIV-infected individuals. However, the lack of expression of viral antigens on latently infected cells makes them difficult to identify or study. Here, we describe a humanized mouse model that can be used to detect latent but reactivatable HIV-1 in both untreated mice and those on ART and therefore provides a simple system with which to study the latent HIV-1 reservoir and the impact of interventions aimed at reducing it.
Sanchez-Gaona N, Perea D, Curran A, Burgos J, Navarro J, Suanzes P Commun Biol. 2025; 8(1):236.
PMID: 39953264 PMC: 11829058. DOI: 10.1038/s42003-025-07651-6.
Reprogramming human B cells with custom heavy-chain antibodies.
Rogers G, Huang C, Mathur A, Huang X, Chen H, Stanten K Nat Biomed Eng. 2024; 8(12):1700-1714.
PMID: 39039240 DOI: 10.1038/s41551-024-01240-4.
The Humanized Mouse Model: What Added Value Does It Offer for HIV Research?.
Baroncini L, Bredl S, Nicole K, Speck R Pathogens. 2023; 12(4).
PMID: 37111494 PMC: 10142098. DOI: 10.3390/pathogens12040608.
An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration.
Virdi A, Ho S, Seaton M, Olali A, Narasipura S, Barbian H Cells. 2023; 12(7).
PMID: 37048107 PMC: 10093470. DOI: 10.3390/cells12071034.
Ollerton M, Folkvord J, Peachman K, Shashikumar S, Morrison E, Jagodzinski L Front Immunol. 2022; 13:1047277.
PMID: 36505432 PMC: 9732419. DOI: 10.3389/fimmu.2022.1047277.